| Published Version Download ( PDF | 905kB) | License: Creative Commons Attribution 4.0 |
Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity
Huss, Muriel, Elger, Tanja, Kunst, Claudia, Loibl, Johanna, Krautbauer, Sabrina, Liebisch, Gerhard
, Kandulski, Arne
, Müller, Martina, Tews, Hauke Christian and Buechler, Christa
(2025)
Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity.
International Journal of Molecular Sciences 26 (9), p. 4034.
Date of publication of this fulltext: 18 Jun 2025 09:21
Article
DOI to cite this document: 10.5283/epub.76892
Abstract
Arachidonic acid levels are elevated in the colonic mucosa of patients with inflammatory bowel disease (IBD). Fecal metabolites are emerging as valuable diagnostic tools for IBD. This study aimed to investigate associations between 31 fecal fatty acids, including arachidonic acid, to identify potential correlations with disease severity. Among the 31 fatty acids analyzed in feces, ...
Arachidonic acid levels are elevated in the colonic mucosa of patients with inflammatory bowel disease (IBD). Fecal metabolites are emerging as valuable diagnostic tools for IBD. This study aimed to investigate associations between 31 fecal fatty acids, including arachidonic acid, to identify potential correlations with disease severity. Among the 31 fatty acids analyzed in feces, dihomo-γ-linolenic acid, arachidonic acid, and adrenic acid were significantly increased in patients with IBD compared to controls. In contrast, levels of linoleic acid and γ-linolenic acid, the precursors of arachidonic acid, were similar between both groups. No significant differences in fatty acid levels were observed between patients with Crohn’s disease and ulcerative colitis. Arachidonic acid and adrenic acid levels positively correlated with fecal calprotectin, a clinically established marker of IBD severity, but showed no association with stool consistency or the Gastrointestinal Symptom Rating Scale. This suggests that these fatty acids are linked to disease severity rather than disease-related symptoms. Current IBD-specific medications had no significant impact on the fecal levels of any of the 31 fatty acids. In summary, this study demonstrates elevated fecal levels of dihomo-γ-linolenic acid, arachidonic acid, and adrenic acid in IBD patients. Normal levels of precursor fatty acids suggest that impaired downstream metabolism may contribute to the accumulation of these n-6 polyunsaturated fatty acids.
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | International Journal of Molecular Sciences | ||||
| Publisher: | MDPI | ||||
|---|---|---|---|---|---|
| Open Access Type: | Gold (with APC) | ||||
| Volume: | 26 | ||||
| Number of Issue or Book Chapter: | 9 | ||||
| Page Range: | p. 4034 | ||||
| Date | 24 April 2025 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin I | ||||
| Identification Number |
| ||||
| Keywords | fatty acids; feces; calprotectin; stool consistency; inflammatory bowel disease; biomarker | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| URN of the UB Regensburg | urn:nbn:de:bvb:355-epub-768927 | ||||
| Item ID | 76892 |
Download Statistics
Download Statistics